BASILEA PHARMACEUTICA AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.9 CHF | -1.35% |
|
+2.45% | +24.36% |
| 03/05 | Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024 | CI |
| 09/04 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 593M | ||||||
| 49.18B | - | |||||
| 42.11B | ||||||
| 40.37B | ||||||
| 28.85B | ||||||
| 26.09B |
